Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Fluarix in Children Previously Vaccinated with Pandemrix
NCT01196026Phase 4Completed
- Sponsor
- GSK
- Start
- Sep 2010
- Primary completion
- May 2011
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of Fluarix in influenza (6 arms), sponsored by GSK. Primary endpoints: Haemagglutination Inhibition (HI) Antibody Titers Against H1N1 at Day 28, Number of Subjects Seropositive for HI Antibodies Against H1N1 at Day 28 and 3 more. Started Sep 2010; status: completed.
02
Drugs
Fluarix
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01196026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01196026.